Anesthesiology Insights

Continuous vs. Bolus Norepinephrine for Post-Induction Hypotension Continuous vs. Bolus Norepinephrine for Post-Induction Hypotension: A Landmark Trial Key Takeaway: Continuous infusion of norepinephrine offers no significant advantage over manual bolus administration in reducing post-induction hypotension in low-to-moderate risk noncardiac surgery patients, according to a randomized trial in the British Journal of Anaesthesia . Study Design Participants: 276 patients (261 analyzed) undergoing elective noncardiac surgery Interventions: Randomized to continuous infusion (target: 0.05 µg/kg/min) or manual boluses (10 µg) Monitoring: Intermittent oscillometric BP + blinded continuous finger-cuff monitoring Primary Endpoint: Area under MAP Key Findings Metric Continuous Infusion Bolus Administration Area under MA...

Danavorexton (TAK-925): A Promising Breakthrough in Combating Opioid-Induced Respiratory Depression Danavorexton (TAK-925): A Promising Breakthrough in Combating Opioid-Induced Respiratory Depression Opioids remain a cornerstone of pain management in clinical settings, yet their use is shadowed by life-threatening side effects, including respiratory depression and excessive sedation. A recent podcast episode from Anesthesiology ’s featured author series highlights a groundbreaking solution: danavorexton (TAK-925) , an orexin receptor 2 agonist that could revolutionize how we manage opioid-related complications. What Is Danavorexton (TAK-925)? Danavorexton is a selective agonist of the orexin-2 receptor (OX2R), a key player in regulating wakefulness and respiration. Orexins (also known as hypocretins) are neuropeptides produced in the hypothalamus that activate OX1R and OX2R receptors, influencing arousal, appetite, and...